AstraZeneca's Evusheld (Tixagevimab co-packaged with Cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected ...
The EU drug regulator advised on Thursday listing blood clots in the brain as a rare side effect of AstraZeneca's COVID-19 after observing cases that were not linked to a low platelet count. ...